INCYTE CORP (INCY) Stock Fundamental Analysis

NASDAQ:INCY • US45337C1027

100.655 USD
-2.33 (-2.27%)
Last: Feb 19, 2026, 10:22 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall INCY gets a fundamental rating of 7 out of 10. We evaluated INCY against 521 industry peers in the Biotechnology industry. INCY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INCY is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make INCY a good candidate for value and quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • INCY had positive earnings in the past year.
  • In the past year INCY had a positive cash flow from operations.
  • In the past 5 years INCY has always been profitable.
  • Each year in the past 5 years INCY had a positive operating cash flow.
INCY Yearly Net Income VS EBIT VS OCF VS FCFINCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • INCY has a Return On Assets of 18.49%. This is amongst the best in the industry. INCY outperforms 96.74% of its industry peers.
  • The Return On Equity of INCY (24.90%) is better than 96.55% of its industry peers.
  • With an excellent Return On Invested Capital value of 19.49%, INCY belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for INCY is significantly below the industry average of 18.69%.
  • The last Return On Invested Capital (19.49%) for INCY is above the 3 year average (10.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 18.49%
ROE 24.9%
ROIC 19.49%
ROA(3y)9.3%
ROA(5y)10.59%
ROE(3y)12.45%
ROE(5y)14.06%
ROIC(3y)10.37%
ROIC(5y)10.71%
INCY Yearly ROA, ROE, ROICINCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • INCY has a better Profit Margin (25.03%) than 95.01% of its industry peers.
  • In the last couple of years the Profit Margin of INCY has grown nicely.
  • The Operating Margin of INCY (26.12%) is better than 95.78% of its industry peers.
  • INCY's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 93.26%, INCY belongs to the best of the industry, outperforming 94.24% of the companies in the same industry.
  • INCY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 26.12%
PM (TTM) 25.03%
GM 93.26%
OM growth 3Y13.93%
OM growth 5YN/A
PM growth 3Y35.6%
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-0.55%
INCY Yearly Profit, Operating, Gross MarginsINCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • INCY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for INCY has been increased compared to 1 year ago.
  • Compared to 5 years ago, INCY has less shares outstanding
  • Compared to 1 year ago, INCY has an improved debt to assets ratio.
INCY Yearly Shares OutstandingINCY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
INCY Yearly Total Debt VS Total AssetsINCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 8.80 indicates that INCY is not in any danger for bankruptcy at the moment.
  • INCY has a Altman-Z score of 8.80. This is amongst the best in the industry. INCY outperforms 81.00% of its industry peers.
  • The Debt to FCF ratio of INCY is 0.03, which is an excellent value as it means it would take INCY, only 0.03 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.03, INCY belongs to the top of the industry, outperforming 96.16% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.01, INCY perfoms like the industry average, outperforming 46.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 8.8
ROIC/WACC2.25
WACC8.68%
INCY Yearly LT Debt VS Equity VS FCFINCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 3.32 indicates that INCY has no problem at all paying its short term obligations.
  • INCY's Current ratio of 3.32 is on the low side compared to the rest of the industry. INCY is outperformed by 60.27% of its industry peers.
  • INCY has a Quick Ratio of 3.25. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
  • INCY's Quick ratio of 3.25 is in line compared to the rest of the industry. INCY outperforms 41.07% of its industry peers.
Industry RankSector Rank
Current Ratio 3.32
Quick Ratio 3.25
INCY Yearly Current Assets VS Current LiabilitesINCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 414.39% over the past year.
  • INCY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.67% yearly.
  • The Revenue has grown by 21.22% in the past year. This is a very strong growth!
  • INCY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.03% yearly.
EPS 1Y (TTM)414.39%
EPS 3Y34.67%
EPS 5YN/A
EPS Q2Q%25.87%
Revenue 1Y (TTM)21.22%
Revenue growth 3Y14.84%
Revenue growth 5Y14.03%
Sales Q2Q%27.84%

3.2 Future

  • The Earnings Per Share is expected to decrease by -7.86% on average over the next years.
  • INCY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.16% yearly.
EPS Next Y17.92%
EPS Next 2Y14.96%
EPS Next 3Y14.58%
EPS Next 5Y-7.86%
Revenue Next Year12.47%
Revenue Next 2Y11.21%
Revenue Next 3Y8.45%
Revenue Next 5Y-1.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INCY Yearly Revenue VS EstimatesINCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
INCY Yearly EPS VS EstimatesINCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • INCY is valuated correctly with a Price/Earnings ratio of 14.82.
  • Based on the Price/Earnings ratio, INCY is valued cheaply inside the industry as 96.16% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.27, INCY is valued a bit cheaper.
  • A Price/Forward Earnings ratio of 12.57 indicates a correct valuation of INCY.
  • INCY's Price/Forward Earnings ratio is rather cheap when compared to the industry. INCY is cheaper than 97.12% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.16, INCY is valued rather cheaply.
Industry RankSector Rank
PE 14.82
Fwd PE 12.57
INCY Price Earnings VS Forward Price EarningsINCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 96.35% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, INCY is valued cheaper than 96.55% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.59
EV/EBITDA 11.27
INCY Per share dataINCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INCY has an outstanding profitability rating, which may justify a higher PE ratio.
  • INCY's earnings are expected to grow with 14.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.83
PEG (5Y)N/A
EPS Next 2Y14.96%
EPS Next 3Y14.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INCY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INCYTE CORP

NASDAQ:INCY (2/19/2026, 10:22:42 AM)

100.655

-2.33 (-2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)04-27
Inst Owners105.27%
Inst Owner Change0.54%
Ins Owners0.96%
Ins Owner Change-10.69%
Market Cap19.76B
Revenue(TTM)5.14B
Net Income(TTM)1.29B
Analysts75
Price Target104.47 (3.79%)
Short Float %5.82%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.64%
Min EPS beat(2)-8.46%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.48%
Min EPS beat(4)-8.46%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.32%
EPS beat(12)5
Avg EPS beat(12)-4.16%
EPS beat(16)7
Avg EPS beat(16)-3.27%
Revenue beat(2)2
Avg Revenue beat(2)7.99%
Min Revenue beat(2)6.72%
Max Revenue beat(2)9.27%
Revenue beat(4)4
Avg Revenue beat(4)5.84%
Min Revenue beat(4)3.45%
Max Revenue beat(4)9.27%
Revenue beat(8)6
Avg Revenue beat(8)2.66%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)9
Avg Revenue beat(16)0.81%
PT rev (1m)2.72%
PT rev (3m)19.27%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)0.49%
EPS NY rev (1m)0.12%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE 14.82
Fwd PE 12.57
P/S 3.84
P/FCF 14.59
P/OCF 13.98
P/B 3.82
P/tB 4.02
EV/EBITDA 11.27
EPS(TTM)6.79
EY6.75%
EPS(NY)8.01
Fwd EY7.95%
FCF(TTM)6.9
FCFY6.86%
OCF(TTM)7.2
OCFY7.15%
SpS26.19
BVpS26.32
TBVpS25.05
PEG (NY)0.83
PEG (5Y)N/A
Graham Number63.41
Profitability
Industry RankSector Rank
ROA 18.49%
ROE 24.9%
ROCE 24.67%
ROIC 19.49%
ROICexc 56.96%
ROICexgc 65.8%
OM 26.12%
PM (TTM) 25.03%
GM 93.26%
FCFM 26.35%
ROA(3y)9.3%
ROA(5y)10.59%
ROE(3y)12.45%
ROE(5y)14.06%
ROIC(3y)10.37%
ROIC(5y)10.71%
ROICexc(3y)33.39%
ROICexc(5y)32.41%
ROICexgc(3y)39.93%
ROICexgc(5y)39.19%
ROCE(3y)13.12%
ROCE(5y)13.56%
ROICexgc growth 3Y17.25%
ROICexgc growth 5YN/A
ROICexc growth 3Y20.23%
ROICexc growth 5YN/A
OM growth 3Y13.93%
OM growth 5YN/A
PM growth 3Y35.6%
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-0.55%
F-Score7
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 63.1%
Cap/Sales 1.15%
Interest Coverage 250
Cash Conversion 98.43%
Profit Quality 105.28%
Current Ratio 3.32
Quick Ratio 3.25
Altman-Z 8.8
F-Score7
WACC8.68%
ROIC/WACC2.25
Cap/Depr(3y)66.35%
Cap/Depr(5y)125.36%
Cap/Sales(3y)1.35%
Cap/Sales(5y)2.48%
Profit Quality(3y)315.54%
Profit Quality(5y)253.68%
High Growth Momentum
Growth
EPS 1Y (TTM)414.39%
EPS 3Y34.67%
EPS 5YN/A
EPS Q2Q%25.87%
EPS Next Y17.92%
EPS Next 2Y14.96%
EPS Next 3Y14.58%
EPS Next 5Y-7.86%
Revenue 1Y (TTM)21.22%
Revenue growth 3Y14.84%
Revenue growth 5Y14.03%
Sales Q2Q%27.84%
Revenue Next Year12.47%
Revenue Next 2Y11.21%
Revenue Next 3Y8.45%
Revenue Next 5Y-1.16%
EBIT growth 1Y1102.71%
EBIT growth 3Y30.84%
EBIT growth 5YN/A
EBIT Next Year29.1%
EBIT Next 3Y3.67%
EBIT Next 5Y-9.44%
FCF growth 1Y443.87%
FCF growth 3Y14.94%
FCF growth 5YN/A
OCF growth 1Y321.52%
OCF growth 3Y13.38%
OCF growth 5YN/A

INCYTE CORP / INCY FAQ

What is the fundamental rating for INCY stock?

ChartMill assigns a fundamental rating of 7 / 10 to INCY.


What is the valuation status of INCYTE CORP (INCY) stock?

ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.


How profitable is INCYTE CORP (INCY) stock?

INCYTE CORP (INCY) has a profitability rating of 9 / 10.


How financially healthy is INCYTE CORP?

The financial health rating of INCYTE CORP (INCY) is 8 / 10.


Can you provide the expected EPS growth for INCY stock?

The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 17.92% in the next year.